On March 20, 2026, Swiss pharma giant Novartis announced the acquisition of Pikavation Therapeutics (a subsidiary of Synnovation Therapeutics) to secure exclusive rights to a promising breast cancer drug candidate. This deal underscores Novartis’ ambition to upgrade existing targeted therapies.
Core components of the deal:
-
Transaction Value: Novartis will pay $2 billion upfront in cash, with potential future milestone payments of up to $1 billion.
-
Flagship Asset: The experimental pill SNV4818, which targets PIK3CA gene mutations—a driver of tumor growth in approximately 40% of patients with HR+/HER2- breast cancer.
-
Technological Breakthrough: Unlike older medications (including Novartis’ own Piqray or Roche’s Itovebi) that inhibit both mutant and healthy enzymes—leading to severe side effects like rashes, GI issues, and hyperglycemia—SNV4818 is designed to selectively target only the mutant form.
-
Therapeutic Benefits: This precision reduces systemic toxicity, enabling consistent dosing and easier combination with other treatments in earlier lines of care.
The drug is currently in early-stage clinical testing, with primary completion expected by 2027. This move follows a series of multi-billion dollar acquisitions by Novartis to strengthen its oncology portfolio.
Source: https://www.biopharmadive.com/news/novartis-synnovation-pikavation-PI3Ka-inhibitor-deal/815283/